- Home
- BGI vs CODX Comparison
BGI vs CODX Comparison
Compare BGI & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- CODX
- Stock Information
- Founded
- BGI 1879
- CODX 2013
- Country
- BGI Canada
- CODX United States
- Employees
- BGI N/A
- CODX N/A
- Industry
- BGI
- CODX Medical/Dental Instruments
- Sector
- BGI
- CODX Health Care
- Exchange
- BGI Nasdaq
- CODX Nasdaq
- Market Cap
- BGI 21.8M
- CODX 22.0M
- IPO Year
- BGI 2005
- CODX 2017
- Fundamental
- Price
- BGI $1.06
- CODX $0.31
- Analyst Decision
- BGI
- CODX Hold
- Analyst Count
- BGI 0
- CODX 1
- Target Price
- BGI N/A
- CODX $1.00
- AVG Volume (30 Days)
- BGI 88.8K
- CODX 274.8K
- Earning Date
- BGI 11-27-2024
- CODX 03-27-2025
- Dividend Yield
- BGI N/A
- CODX N/A
- EPS Growth
- BGI N/A
- CODX N/A
- EPS
- BGI N/A
- CODX N/A
- Revenue
- BGI $131,596,265.00
- CODX $3,915,160.00
- Revenue This Year
- BGI N/A
- CODX N/A
- Revenue Next Year
- BGI N/A
- CODX N/A
- P/E Ratio
- BGI N/A
- CODX N/A
- Revenue Growth
- BGI 4.01
- CODX N/A
- 52 Week Low
- BGI $0.93
- CODX $0.28
- 52 Week High
- BGI $3.31
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- BGI 52.89
- CODX 29.41
- Support Level
- BGI $1.03
- CODX $0.32
- Resistance Level
- BGI $1.36
- CODX $0.39
- Average True Range (ATR)
- BGI 0.10
- CODX 0.06
- MACD
- BGI 0.01
- CODX -0.00
- Stochastic Oscillator
- BGI 63.64
- CODX 18.33
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.